117 related articles for article (PubMed ID: 21296193)
1. Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature.
Ingegnoli F; Favalli EG; Meroni PL
Autoimmun Rev; 2011 Jun; 10(8):460-3. PubMed ID: 21296193
[TBL] [Abstract][Full Text] [Related]
2. An update on pharmacogenomics in rheumatoid arthritis with a focus on TNF-blocking agents.
Ranganathan P
Curr Opin Mol Ther; 2008 Dec; 10(6):562-7. PubMed ID: 19051134
[TBL] [Abstract][Full Text] [Related]
3. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
4. Genetic and genomic predictors of anti-TNF response.
Prajapati R; Plant D; Barton A
Pharmacogenomics; 2011 Nov; 12(11):1571-85. PubMed ID: 22044414
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
Choy E
Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
[TBL] [Abstract][Full Text] [Related]
6. [Current aspects of cost effectiveness of TNF-alpha blocking agents in patients with rheumatoid arthritis].
Merkesdal S; Ruof J
Z Rheumatol; 2002; 61 Suppl 2():II/29-32. PubMed ID: 12491120
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis.
Ranganathan P
Pharmacogenomics; 2005 Jul; 6(5):481-90. PubMed ID: 16013998
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants that predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis: current challenges and future directions.
Plenge RM; Criswell LA
Curr Opin Rheumatol; 2008 Mar; 20(2):145-52. PubMed ID: 18349743
[TBL] [Abstract][Full Text] [Related]
9. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
10. [Proposal for anti-TNFalpha therapy in adult patients with rheumatoid arthritis].
Curković B; Babić-Naglić D; Morović-Vergles J; Anić B; Grazio S
Reumatizam; 2007; 54(1):16-9. PubMed ID: 18450272
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacogenomics of antirheumatic drugs and personalized medicine for rheumatoid arthritis].
Taniguchi A; Urano W; Tanaka E; Kamatani N
Nihon Rinsho; 2007 Feb; 65(2):371-9. PubMed ID: 17302286
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics in rheumatoid arthritis.
Ranganathan P
Methods Mol Biol; 2008; 448():413-35. PubMed ID: 18370240
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs.
Avouac J; Allanore Y
Expert Opin Pharmacother; 2008 May; 9(7):1121-8. PubMed ID: 18422470
[TBL] [Abstract][Full Text] [Related]
14. Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis.
Braun-Moscovici Y; Markovits D; Zinder O; Schapira D; Rozin A; Ehrenburg M; Dain L; Hoffer E; Nahir AM; Balbir-Gurman A
J Rheumatol; 2006 Mar; 33(3):497-500. PubMed ID: 16511906
[TBL] [Abstract][Full Text] [Related]
15. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
[TBL] [Abstract][Full Text] [Related]
16. Predictors of response to TNF inhibitors in rheumatoid arthritis - do we have new tools for personalized medicine?
Simsek I
Bull NYU Hosp Jt Dis; 2012; 70(3):187-90. PubMed ID: 23259626
[TBL] [Abstract][Full Text] [Related]
17. Personalized medicine in rheumatoid arthritis: hopes and challenges.
Bridges SL
Bull NYU Hosp Jt Dis; 2007; 65(3):174-7. PubMed ID: 17922665
[TBL] [Abstract][Full Text] [Related]
18. The need for personalised medicine for rheumatoid arthritis.
Isaacs JD; Ferraccioli G
Ann Rheum Dis; 2011 Jan; 70(1):4-7. PubMed ID: 21068091
[TBL] [Abstract][Full Text] [Related]
19. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study.
Klaasen R; Thurlings RM; Wijbrandts CA; van Kuijk AW; Baeten D; Gerlag DM; Tak PP
Arthritis Rheum; 2009 Nov; 60(11):3217-24. PubMed ID: 19877042
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease?
Feldmann M; Brennan FM; Paleolog E; Cope A; Taylor P; Williams R; Woody J; Maini RN
Novartis Found Symp; 2004; 256():53-69; discussion 69-73, 106-11, 266-9. PubMed ID: 15027483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
